SABCS 2021 | How useful are checkpoint inhibitors in the treatment of breast cancer?
Timothy Yap, MBBS, PhD, FRCP, University of Texas MD Anderson Cancer Center, Houston, TX, discusses how useful checkpoint inhibitors are in the treatment of breast cancer, and which patients would benefit most from this treatment. Checkpoint inhibitors that are approved by the FDA for the treatment of breast cancer include pembrolizumab and dostarlimab. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
Disclosures
Research support (to Institution): Repare, AstraZeneca, Artios, Bayer, Beigene, BioNTech, BMS, Clovis, Constellation, Cyteir , Eli Lilly, EMD Serono, Forbius, F-Star, Artios, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro and Vivace
Consultancies: Repare, AstraZeneca, Almac, Aduro, Artios, Athena, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, GLG, Guidepoint, Ignyta, I-Mab, ImmuneSensor, Jansen, Merck, Pfizer, Roche, Schrodinger, Seattle Genetics, Varian, Zai Labs and ZielBio
